Publicacions
El coneixement generat a IrsiCaixa es comparteix amb la comunitat científica a través de la publicació d’articles a revistes científiques d’alt impacte.
Host genetic and immune factors drive evasion of HIV-1 pathogenesis in viremic non-progressors.
Preclinical development of humanized monoclonal antibodies against CD169 as a broad antiviral therapeutic strategy.
Impact of obefazimod on viral persistence, inflammation, and immune activation in people with HIV on suppressive antiretroviral therapy.
Author Correction to: SARS-CoV-2 interaction with Siglec-1 mediates trans-infection by dendritic cells.
Dissemination of Mycobacterium tuberculosis is associated to a SIGLEC1 null variant that limits antigen exchange via trafficking extracellular vesicles
SARS-CoV-2 interaction with Siglec-1 mediates trans-infection by dendritic cells.
Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen.
Anti-Siglec-1 antibodies block Ebola viral uptake and decrease cytoplasmic viral entry.
Dendritic Cells From the Cervical Mucosa Capture and Transfer HIV-1 via Siglec-1.
Long-Term Spontaneous Control of HIV-1 Is Related to Low Frequency of Infected Cells and Inefficient Viral Reactivation.